GlassScriptPhysician profile
Michael J Dugan
NPI 1437263399
$236,220.58
in general payments reported to CMS, 2019-2025
17 companies · $52.27 in 2025
The $52.27 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74K · 2020: $42K · 2021: $28K · 2022: $37K · 2023: $55K · 2024: $57.50 · 2025: $52.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $47K · Travel and Lodging: $7,564 · Food and Beverage: $967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,612.50 |
| Travel and Lodging | $7,564.25 |
| Food and Beverage | $966.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $124,944.26 | 2019-2023 | Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $91,198.60 | 2020-2023 | Pomalyst |
| Jazz Pharmaceuticals INC. | $10,335.07 | 2019-2020 | |
| Pfizer INC. | $4,032.91 | 2019 | |
| Janssen Biotech, INC. | $3,484.41 | 2019 | |
| Adaptive Biotechnologies Corporation | $1,511.35 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $258.76 | 2022-2023 | Darzalex, Tecvayli |
| Amgen INC. | $137.93 | 2020-2022 | |
| Astellas Pharma US INC | $104.95 | 2019 | |
| Seagen INC. | $46.33 | 2022 | |
| Alexion Pharmaceuticals, INC. | $35.34 | 2024 | Ultomiris |
| Abbvie INC. | $26.61 | 2025 | |
| Stryker Corporation | $25.66 | 2025 | Flowtriever |
| Kite Pharma, INC. | $23.79 | 2022 | |
| Novartis Pharmaceuticals Corporation | $22.16 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $17.39 | 2019 | |
| Agios Pharmaceuticals, INC. | $15.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dugan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.